Latest news with #PMB
TimesLIVE
30-06-2025
- Business
- TimesLIVE
Affordable cover, more benefits, no hassle: Medshield membership rises
Medshield Medical Scheme recently held its 56th AGM where principal officer Kevin Aron highlighted the scheme's impressive performance for the financial year ending December 31 2024. Despite a challenging economic environment, Medshield has maintained a healthy solvency ratio and strong credit rating. This demonstrates the scheme's ability to meet its obligations and ensure long-term stability and sustainability for its members. Even in a stagnant market, Medshield ensured affordability without compromising quality of care, and kept its 2024 contributions low while increasing member benefits. This resulted in a 2.57% rise in membership in 2024. Living up to its commitment to be 'Your Partner for Life', Medshield has many members who have been with the scheme for more than 18 years, knowing it has their best interests at heart. Member-centric benefit plans for every stage of life First, there is no guarantee that your health will always be good enough to cover your medical expenses out of pocket. Second, medical aid should never be a complicated, grudge purchase. That's the reason Medshield makes it easy for you by offering a benefit plan tailored for every stage of your life: In your 20s: MediCurve is ideal for young, healthy, tech-savvy, first-time medical-aid buyers. This affordable plan enables young adults to acquire healthcare cover without putting any financial strain on their day-to-day lives. MediCurve offers in-hospital and out-of-hospital benefits, including free, unlimited virtual family practitioner consultations through its Medshield SmartCare benefit. MediPhila aims to protect young families against unforeseen medical costs through unlimited hospital cover for Prescribed Minimum Benefits (PMB) conditions. There are also beneficiary limits for non-PMB in-hospital treatments and an out-of-hospital benefit limit for specific services. In your 30s: MediValue is the ideal option for individuals needing unlimited hospital and day-to-day partial cover. This option is available in both the Prime and Compact categories. The benefits are the same, but the Compact category mandates the use of Medshield Provider Networks for a smaller contribution. MediSaver is perfect for independent individuals who want to manage their out-of-hospital healthcare expenses through a personal savings account with unlimited hospital cover. Reaching your 40s and beyond: MediPlus is the answer for middle- to upper-income earners. It offers unlimited in-hospital coverage and a generous day-to-day limit. This option is available in the Prime and Compact categories. Both benefits are the same but, in return for a smaller contribution, the Compact category mandates the use of Medshield Provider Networks. MediBonus is the best choice for corporate employees and individuals who need comprehensive unlimited in-hospital cover and extensive day-to-day benefits. PremiumPlus provides the most comprehensive cover with freedom of choice, including no network restrictions, 200% cover for specific in-hospital procedures, and a personal savings account to manage your daily healthcare. At any stage: MediCore: Perhaps you're not one to visit the doctor for routine checks, but at the very least everyone should have unlimited in-hospital cover in case of major medical emergencies. MediCore is a hospital plan for those who require unlimited hospital cover with full PMB cover. Certain in-hospital procedures are paid for at a higher rate (Medshield Private Tariff 200%). 'No hassle' service excellence Medshield continues to innovate and improve its services, ensuring alignment with international best practice as evidenced by the scheme's International Organisation for Standardization (ISO) 9001:2015 accreditation. This demonstrates its commitment to quality and customer satisfaction. The scheme prioritises having the right capabilities and competencies to provide the highest quality customer service. Medshield embraces innovation that fosters closer relationships with members. The launch of a new member app at the end of 2024 enhanced access to information and communication. 'Innovation is at the heart of Medshield. Our member app saw a 12.5% increase in downloads and a 35.6% boost in utilisation, making healthcare management more efficient than ever,' says Aron. In addition to the member app, the scheme offers many other self-service touch points including its WhatsApp service line, the website member log-in zone and its Let's Meet virtual Microsoft Teams meeting solution. For members who prefer in-person service, the scheme continues to offer in-person visits to regional offices and telephone interactions through its state-of-the-art contact centre.
Korea Herald
20-05-2025
- Health
- Korea Herald
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response
IRVINE, Calif., May 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc. (PMB) a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first r/r FL patient treated in its phase 1 PMB-102 study, r/r B-cell non-Hodgkin's Lymphoma (r/r B-NHL) trial of PMB-CT01 (BAFFR-CAR T Cells), has achieved complete remission at one month post treatment. "We are excited to report that a patient with r/r FL has achieved complete remission after treatment with PMB-CT01, bringing the total to seven patients-all achieving a 100% CR rate with durable responses and a manageable safety profile. Notably, this patient had previously undergone 7 prior lines of therapy including chemoimmunotherapies, CD19 CAR T cells, an investigational trispecific antibody, and an antibody-drug conjugate (ADC). Remarkably, the patient experienced no CRS or ICANS," said Elizabeth Budde M.D., Ph.D., the trial's lead principal investigator and associate professor of hematology at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. Follicular lymphoma (FL) is the most common indolent (slow-growing) form of B-cell non-Hodgkin Lymphoma (NHL), accounting for 20% of NHL in the US. [1] FL is considered incurable with current standard of care therapies. [2] Patients often relapse and with each relapse, the remission and time to next treatment is shorter. [3] Patients with r/r FL are in need of additional medical options. "IFLI is dedicated to accelerating the development of innovative treatment options for patients with r/r FL" stated Dr. Michel Azoulay, M.D., CMO of the Institute for Follicular Lymphoma Innovation. "I am very excited that PMB-CT01 has shown promising efficacy and safety in this first FL patient." "Most of the PMB-102 trial participants relapsed after CD19 CAR T therapy and/or presented with CD19 negative tumors. PMB-CT01 could present a viable alternative option for patients facing this challenging scenario," said Hazel Cheng PhD., COO of PMB. "We are deeply committed to the development of this first-in-class BAFFR CAR T therapy and are excited to advance our study into a multi-site expansion phase that will include r/r MCL, DLBCL and FL patients." About PMB-CT01 PMB-CT01 is a first-in-class, BAFF-R targeted, autologous CAR T cell therapy. BAFF-R (B-Cell Activating Factor Receptor), a member of the tumor necrosis factor (TNF) receptor superfamily, is the main receptor for BAFF and is expressed almost exclusively on B cells. Since BAFF-R signaling promotes normal B-cell proliferation and appears to be required for B-cell survival, tumor cells are unlikely to escape therapy via loss of the BAFF-R antigen. This unique characteristic makes BAFF-R CAR T therapy a highly promising option for treating B-cell malignancies PMB-CT01 (BAFFR-CAR T cells) is currently being investigated to treat relapsed and refractory B-cell non-Hodgkin's lymphoma (B-NHL; NCT05370430), B-cell, acute lymphoblastic leukemia (B-ALL; NCT04690595) in phase 1 clinical trials. Early results from PMB-101 and PMB-102 have demonstrated PMB-CT01 to be high activity and tolerable in heavily pre-treated r/r ALL and r/r NHL patient populations. PeproMene Bio has licensed intellectual property relating to PMB-CT01 from City of Hope. About PeproMene Bio PeproMene Bio, Inc. is a clinical-stage biotech company based in Irvine, California and is focused on the clinical development of novel therapies to treat B-cell malignancies and autoimmune disorders including BAFF-R CAR-T cell therapy and BAFF-R bispecific T cell engager therapy. Learn more at About iFLI The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology leading to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at
Sky News
20-03-2025
- Entertainment
- Sky News
Adolescence writers 'invited to parliament' to discuss show's themes with MPs, Sky News understands
The creators of Netflix drama Adolescence have been invited to parliament to discuss online safety with MPs, Sky News understands. Labour's Josh MacAlister has been in touch with representatives of actor Stephen Graham and his co-writer Jack Thorne about the possibility of a meeting, it is understood. MPs are keen to discuss themes raised in the chart-topping show, which centres on a 13-year-old boy arrested for the murder of a young girl and the rise of incel culture. It arrived amid mounting concern over violent and sexist social media content being served up to teenagers, and calls for the government to get tough on tech firms. Graham and Thorne have expressed a desire for the series to be shown in schools and parliament to start a conversation about how to better protect children. 1:30 PM wants to tackle 'abhorrent' trend Sir Keir Starmer gave that campaign his backing yesterday, revealing at PMQs he had been watching the drama with his teenage children. "This violence carried out by young men, influenced by what they see online, is a real problem," he said. "It's abhorrent, and we have to tackle it." Culture Secretary Lisa Nandy told Sky News the issues raised in Adolescence were ones the government should be "acutely aware of". And Labour MP Johnathan Brash, who has an eight-year-old boy, said he would back showing parts of the show to primary school children so they can learn about the harms of social media before they start using it. Mr MacAlister is the MP behind the safer phones legislation, which aimed to stop children "doom-scrolling" by raising the age of consent to use social media from 13 to 16. However, his private members bill (PMB) had to be watered down to get government support - as PMBs don't usually pass without it. 0:49 Call for social media age of consent to be raised In an interview with BBC Newsnight on Wednesday, Thorne said he hoped the debate sparked by Adolescence could "provoke" the government into change. He pointed out Australia is set to enforce a social media ban for young children, making platforms liable for fines of up to A$50m (£25m) if they don't prevent those younger than 16 from holding accounts. The Online Safety Act, which is being implemented this year, is intended to protect young people from illegal and harmful content with fines for platforms who break the rules coming in this summer. However, MPs from across the political spectrum want further action to tackle the amount of time children spend on their smartphones.
Yahoo
07-02-2025
- Business
- Yahoo
Two PMB Projects Named 2024 HREI Insights™ Award Winners
Healthcare Real Estate Insights™ magazine's national awards program honors multiple healthcare projects completed by PMB in 2024. SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- PMB's Providence Swedish Rehab Hospital and The Springs Living at Vancouver Waterfront seniors housing community have been named as Winners in Healthcare Real Estate Insights (HREI) magazine's annual, national awards program. "PMB is honored to win these prestigious awards which recognize the dedication and teamwork that went into these healthcare real estate projects," says Mark D. Toothacre, Managing Partner and CEO of PMB. "These two winning projects are addressing critical needs in their respective communities." The Springs Living at Vancouver Waterfront was named The Best Post-Acute & Senior Living Facilities Best New Ground-Up Development. The new twelve-story, 360,000 SF, 250-unit community for older adults is located at 1015 W Columbia Way, as part of the Waterfront Master Plan in Vancouver, Wash. Designed as an optimum environment for the health and well-being of residents and staff, the community has been designed with the intention of meeting the rigorous standards for LEED Gold Certification which rates systems for the design, construction, operation, and maintenance of green buildings, as well as FitWel Certification which uses evidence-based design and operational strategies to optimize occupant health. The Springs at The Waterfront provides a continuum of care options for its residents, including 182 independent living units, 48 assisted living units, and 20 memory care units. In addition, The Providence Swedish Rehabilitation Hospital was named the Best in Hospitals and Other Inpatient Facilities Best New Ground-Up Development. The new 2-story, 53,000 square-foot inpatient rehabilitation facility in Lynwood, Washington, is outfitted with patient centric amenities and adaptive units, including an 8-bed brain injury unit, a dialysis suite, and multidisciplinary therapy gymnasiums. A specialized suite, in addition to a therapy kitchen and laundry area, give patients the opportunity to work through activities of daily living, and a therapeutic courtyard is outfitted with exterior amenities designed to promote patient ambulation and activity. The rehabilitation hospital also includes private rooms for patient and family comfort, an acquired brain injury unit with private dining and therapy gym, large interdisciplinary gyms, a therapeutic courtyard with golf and varied surfaces, and a transitional living apartment to prepare patients for daily living tasks before they are discharged home. In addition, PMB's UChicago Medicine Northwest Indiana Expansion, a 131,000 square-foot development, was named a finalist in the New Medical Office Buildings and Other Outpatient Facilities (100,000 square feet or more). PMB's projects have been named finalists 18 times, ten of which won top project awards in the previous years of the HREI Insights Awards program including PMB's CEO and Managing Partner, Mark Toothacre, as Healthcare Real Estate Executive of the Year in 2020. The HREI Insights Awards are the only national awards dedicated to recognizing excellence in the areas of HRE development and executive leadership. The awards are presented by HREI, the first and only national magazine entirely devoted to covering HRE development, financing and investment. About PMBPMB is a purpose-driven healthcare real estate developer with a mission to improve healthcare delivery, effect change, and positively impact communities. Our company is 100 percent focused on healthcare real estate across the continuum of care including behavioral health, life sciences, ambulatory care centers, medical office buildings, inpatient hospitals, post-acute hospitals, senior living facilities, and parking structures. PMB has developed over 130 facilities to date representing approximately $6.5 billion dollars and 6.5 million square feet. The firm owns and manages over 70 medical facilities comprising over 5.5 million square feet. For more information, please visit our website at View original content to download multimedia: SOURCE PMB Sign in to access your portfolio
